Paul Truex
Vorstandsvorsitzender bei Thryv Therapeutics, Inc.
Profil
Paul F.
Truex founded Peninsula Pharmaceuticals, Inc. in 2001, where he worked as President, Chief Executive Officer & Director from 2004 to 2005, Anthera Pharmaceuticals, Inc. in 2004, where he worked as Executive Chairman from 2016 to 2018, and Thryv Therapeutics, Inc. in 2019, where he is working as Executive Chairman & Chief Executive Officer.
Mr. Truex also currently works at Gladius Pharmaceuticals, Inc., as Executive Chairman from 2018, Find Therapeutics, as Chairman from 2022, Waterloo Pharmaceuticals, Inc., as Director, and Feldan Bio, Inc., as Director from 2018.
Mr. Truex also formerly worked at CymaBay Therapeutics, Inc., as Independent Director from 2016 to 2021, InteKrin Therapeutics, Inc., as Director, Milestone Pharmaceuticals, Inc., as Independent Non-Executive Director from 2019 to 2022, Eiger BioPharmaceuticals, Inc., as Director, Trius Therapeutics, Inc., as Independent Director from 2011 to 2013, Protagonist Therapeutics, Inc., as Independent Director, Eli Lilly & Co., as Principal, and Vicuron Pharmaceuticals LLC, as Vice President-Commercial Development from 2000 to 2001.
Mr. Truex received his Masters Business Admin degree in 1997 from Indiana University and undergraduate degree in 1991 from The University of Waterloo.
Aktive Positionen von Paul Truex
| Unternehmen | Position | Beginn |
|---|---|---|
| Waterloo Pharmaceuticals, Inc. | Direktor/Vorstandsmitglied | - |
Thryv Therapeutics, Inc.
 Thryv Therapeutics, Inc. Medical/Nursing ServicesHealth Services LQT Therapeutics, Inc. engages in the development of therapies for the treatment of all forms of Long QT Syndrome. The company was founded by Anthony Rosenzweig, Saumya Das and David Milan and is headquartered in Laval, Canada. | Vorstandsvorsitzender | - |
Gladius Pharmaceuticals, Inc.
 Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Vorsitzender | 01.11.2018 |
Feldan Bio, Inc.
 Feldan Bio, Inc. Pharmaceuticals: MajorHealth Technology Feldan Bio, Inc. develops, produces and supplies recombinant proteins for therapeutic and research purposes. It specializes in cell culture products, cytokines, enzymes, receptors, clinical grade cytokines, and research proteins. The company was founded by Fran?ois-Thomas Michaud and Francois-Eric Lebeau in 2007 and is headquartered in Quebec, Canada. | Direktor/Vorstandsmitglied | 01.04.2018 |
Find Therapeutics
 Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Vorsitzender | 01.08.2022 |
Ehemalige bekannte Positionen von Paul Truex
| Unternehmen | Position | Ende |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Vorsitzender | 01.02.2019 |
| CYMABAY THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.04.2021 |
| ANTHERA PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 01.12.2016 |
Trius Therapeutics, Inc.
 Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 11.09.2013 |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Paul Truex
| Indiana University | Masters Business Admin |
| The University of Waterloo | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ANTHERA PHARMACEUTICALS, INC. | Health Technology |
| MILESTONE PHARMACEUTICALS INC. | Health Technology |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
CymaBay Therapeutics, Inc.
 CymaBay Therapeutics, Inc. BiotechnologyHealth Technology CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA. | Health Technology |
Peninsula Pharmaceuticals, Inc.
 Peninsula Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Peninsula Pharmaceuticals, Inc. used to develop and commercialize antibiotics to treat life threatening infections. The company used to develop optimal anti-infective therapies that offer improved efficacy, dosing and safety characteristics over existing therapies. It was founded in 2001. The company was located in Alameda, CA. | Commercial Services |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Health Technology |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | Health Technology |
| Waterloo Pharmaceuticals, Inc. | |
Feldan Bio, Inc.
Feldan Bio, Inc. Pharmaceuticals: MajorHealth Technology Feldan Bio, Inc. develops, produces and supplies recombinant proteins for therapeutic and research purposes. It specializes in cell culture products, cytokines, enzymes, receptors, clinical grade cytokines, and research proteins. The company was founded by Fran?ois-Thomas Michaud and Francois-Eric Lebeau in 2007 and is headquartered in Quebec, Canada. | Health Technology |
Gladius Pharmaceuticals, Inc.
Gladius Pharmaceuticals, Inc. BiotechnologyHealth Technology Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec. | Health Technology |
Thryv Therapeutics, Inc.
Thryv Therapeutics, Inc. Medical/Nursing ServicesHealth Services LQT Therapeutics, Inc. engages in the development of therapies for the treatment of all forms of Long QT Syndrome. The company was founded by Anthony Rosenzweig, Saumya Das and David Milan and is headquartered in Laval, Canada. | Health Services |
Find Therapeutics
Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
